Abstracts Archive - Page 847 of 2607 - ACR Meeting Abstracts

Abstract Number: 0159 • ACR Convergence 2020
Patient-Reported Data Show the Impact of Time to Diagnosis in RA
Kelly O'Neill¹, Kathryne Marks², John Davis³ and Cynthia Crowson⁴, ¹Rheumatoid Patient Foundation, Orlando, FL, ²Rosalind Franklin University of Medicine and Science, North Chicago, IL, ³Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: Time from diagnosis to treatment has been well established to correlate with better outcomes in rheumatoid arthritis (RA). Treatment delays are often associated with…
Abstract Number: 0160 • ACR Convergence 2020
Use of PROMIS29 Across Inflammatory Arthritis: Score Distributions and Impact of Contextual Factors
Alexis Ogdie¹, Kaleb Michaud², Mark Hwang³, Sofia Pedro⁴ and Patricia Katz⁵, ¹University of Pennsylvania, Philadelphia, PA, ²FORWARD-The National Data Bank for Rheumatic Diseases; University of Nebraska Medical Center, Wichita, ³McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ⁴FORWARD-The National Data Bank for Rheumatic Diseases, Wichita, ⁵University of California, San Francisco, Novato, CA
Background/Purpose: The Patient-Reported Outcome Measure Information System (PROMIS) includes a set of instruments developed to measure physical, mental and social health. PROMIS measures have been…
Abstract Number: 0161 • ACR Convergence 2020
Validation of Patient-reported Outcomes (PRO) Lung Questionnaires for Systemic Juvenile Idiopathic Arthritis (SJIA) Patients at Risk for Lung Disease
Kim Nguyen¹, Christopher Towe², Shima Yasin³, Alexei Grom⁴, Hermine I Brunner⁵ and Grant Schulert⁵, ¹Veterans Affairs Cincinnati, University of Cincinnati Medical Center, Cincinnati, ²Cincinnati Children's Medical Hospital Center, Cincinnati, ³Cincinnati Children's Hospital Medical Center, Cincinnati, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (SJIA) involves dysregulation of inflammation and innate immunity, and can cause life-threatening complications including lung disease (LD). However, there are…
Abstract Number: 0162 • ACR Convergence 2020
Identifying Sleep Problems in Systemic Juvenile Idiopathic Arthritis (SJIA) Patients with Patient-reported Outcomes (PRO) Questionnaires
Kim Nguyen¹, Christopher Towe², Shima Yasin³, Alexei Grom⁴, Hermine I Brunner⁵ and Grant Schulert⁵, ¹Veterans Affairs Cincinnati, University of Cincinnati Medical Center, Cincinnati, ²Cincinnati Children's Medical Hospital Center, Cincinnati, ³Cincinnati Children's Hospital Medical Center, Cincinnati, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (SJIA) can cause severe and chronic multisystem involvement. Medical therapies including high-dose corticosteroids can have significant side effects affecting sleep.…
Abstract Number: 0163 • ACR Convergence 2020
Cost of Non-Persistence in the Treatment with Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors of Inflammatory Arthritis: A Propensity Score Matching Approach
Johan Dalén¹, Karin Luttropp¹, Tor Olofsson², Christopher Black³ and Amy Puenpatom⁴, ¹ICON plc, Stockholm, Sweden, Stockholm, Sweden, ²Department of Clinical Sciences, Lund, Rheumatology, Lund University, Sweden; Department of Rheumatology, Skåne University Hospital, Lund, Sweden, Lund, Sweden, ³Merck & Co., Inc., Kenilworth, NJ, USA, Rahway, NJ, ⁴Merck & Co., Inc., Kenilworth, NJ, USA, North Wales, PA
Background/Purpose: Few studies have explored cost consequences of non-persistence in the treatment with Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors (SC-TNFi) in Inflammatory Arthritis (IA; rheumatoid arthritis…
Abstract Number: 0164 • ACR Convergence 2020
What’s in a Name? Patient and Family Perspectives on the Naming of Systemic Juvenile Idiopathic Arthritis
Mariana Correia Marques¹, Rashmi Sinha², Karen Durrant³, Sivia Lapidus⁴, Nicole Tennermann⁵, Saskya Angevare⁶, Leah Bush⁷, Kari Cupp⁸, Jonathan Hausmann⁹, David Maher¹⁰, Shalla Newton¹⁰, Michael Ombrello¹¹, Phillip Reardon⁸, Rebecca Trachtman¹², Fatma Dedeoglu⁵ and Grant Schulert¹³, ¹Boston Children`s Hospital, Department of Pediatrics, Harvard Medical School, Boston, MA, ²SJIA Foundation, Cincinnati, ³Autoinflammatory Alliance, San Francisco, CA, ⁴The Joseph M. Sanzari Children's Hospital, Hackensack Meridian Health, Montclair, NJ, ⁵Boston Children's Hospital, Boston, MA, ⁶Autoinflammatory Alliance, Amersfoort, Netherlands, ⁷Systemic JIA Foundation, Cincinnati, OH, ⁸Systemic JIA Foundation, Cincinnati, ⁹Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ¹⁰Still's Disease, the 411, National organization, ¹¹Translational Genetics and Genomics Unit, NIAMS, NIH, Bethesda, MD, ¹²Icahn School of Medicine at Mount Sinai, New York, NY, ¹³PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: The childhood inflammatory disorder systemic juvenile idiopathic arthritis (SJIA) has historically had several names, including Still’s disease and systemic juvenile rheumatoid arthritis. While its…
Abstract Number: 0165 • ACR Convergence 2020
Work Disability and Predictors of Poor Work Outcome in Patients with Axial Spondyloarthritis
Elif Ediboglu¹, Dilek Solmaz², Hande Ece Oz³, Gokhan Kabadayı⁴, Haluk Cinaklı⁴, Eda Otman Akat³, Mustafa Ozmen⁴ and Servet Akar³, ¹Izmir Katip Celebi University, Izmir, Izmir, Turkey, ²Izmir Katip Celebi University, Department of Internal Medicine, Division of Rheumatology, Izmir, TURKEY, Izmir, Turkey, ³Izmir Katip Celebi University, Izmir, Turkey, ⁴Izmir Katip Celebi University, Izmir
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease which may lead substantial functional limitation. The disease more commonly affects men in their third decade…
Abstract Number: 0166 • ACR Convergence 2020
Prevalence and Impact of Unacceptable Symptom State Among Patients with Psoriatic Arthritis: Results from the National Psoriasis Foundation’s 2019 Annual Survey
Alexis Ogdie¹, George Gondo², Joseph Merola³, Stacie Bell⁴ and Alice Gottlieb⁵, ¹University of Pennsylvania, Philadelphia, PA, ²National Psoriasis Foundation, Portland, OR, ³Brigham and Women's Hospital, Harvard Medical School, Newton, MA, ⁴National Psoriasis Foundation, Portland, ⁵Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Despite many efficacious therapies for PsA, many patients do not achieve remission. Ongoing disease activity leads to many downstream effects including diminished functional ability,…
Abstract Number: 0167 • ACR Convergence 2020
Rheumatoid Arthritis Patient Phenotypes from a Digital Health Coaching Engagement Program
Jonathan Patterson¹, Kirby Magid², Dhiren Patel³ and Matt Allison³, ¹Pack Health, Birmingham, AL, ²University of North Carolina at Charlotte, Charlotte, ³Pack Health, Birmingham
Background/Purpose: The goal of this study was to examine whether cluster analysis could be used to identify homogeneous subgroups of engagement in RA patients enrolled…
Abstract Number: 0168 • ACR Convergence 2020
Impact of Adalimumab (Humira) Therapy on Ocular Inflammation, Selected Health Care Resource Utilization, and Patient-Reported Outcomes in Patients with Active Non-infectious Intermediate, Posterior, or Panuveitis in Routine Clinical Practice
Uwe Pleyer¹, Salem Almutairi², Conor Murphy³, Rola Hamam⁴, Karina Julian⁵, Shereen Hammad⁶, Orsolya Nagy⁷, Zohar Habot-Wilner⁸, Zsuzsanna Szepessy⁹, Yan Guex-Crosier¹⁰ and Sofia Androudi¹¹, ¹Charité Universitätsmedizin Berlin, Klinik für Augenheilkunde, Berlin, Germany, ²Al-Bahar Ophthalmology Center - Al-Sabah Hospital, Kuwait City, Kuwait, ³Royal Victoria Eye & Ear Hospital, Dublin, Ireland, ⁴American University of Beirut, Beirut, Lebanon, ⁵Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates, ⁶AbbVie Biopharmaceuticals GmbH, Dubai, United Arab Emirates, ⁷AbbVie Kft, Budapest, Hungary, ⁸Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel, ⁹Semmelweis University, Budapest, Hungary, ¹⁰Jules-Gonin Eye Hospital, Department of Ophthalmology, University of Lausanne, Lausanne, Switzerland, ¹¹University of Thessaly, Larissa, Greece
Background/Purpose: VISUAL clinical trials demonstrated efficacy and safety of adalimumab (ADA) in patients with active and inactive non-infectious, intermediate, posterior, or panuveitis (NIIPPU).1-3 The purpose…
Abstract Number: 0169 • ACR Convergence 2020
Patient-Reported Outcomes Differentiate Between Remission and Low Disease Activity in Psoriatic Arthritis
Juliette Yedimenko¹, Jessica Walsh², Alexis Ogdie³, Yuxuan Jin¹, Soumya Reddy⁴, Jose Scher⁵ and M. Elaine Husni¹, ¹Cleveland Clinic, Cleveland, OH, ²University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT, ³Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁴NYU School of Medicine, New York, NY, ⁵NYU School of Medicine, New York City
Background/Purpose: For psoriatic arthritis (PsA), several different composite instruments are available to define low disease activity (LDA) and remission (REM) targets for treatment. Patient-reported outcomes…
Abstract Number: 0170 • ACR Convergence 2020
Utilizing Design Thinking to Develop a Decision Aid for Patients with Psoriasis and Psoriatic Arthritis
Marilyn Wan¹, Michele Almonte², Joel Gelfand¹ and Alexis Ogdie², ¹University of Pennsylvania, Philadelphia, ²University of Pennsylvania, Philadelphia, PA
Background/Purpose: Given the complexity of available treatment recommendations, patients with psoriatic disease would benefit from a process fostering shared decision-making using a patient-centered approach. True…
Abstract Number: 0171 • ACR Convergence 2020
Interferon Response Gene Expression Differs in Whole Blood, Peripheral Blood Mononuclear Cells, Monocytes, T Cells, B Cells, and NK Cells in Patients with the Autoinflammatory Interferonopathies, CANDLE and SAVI
Jacob Mitchell¹, Sara Alehashemi², Bernadette Marrero³, Yan Huang⁴, Sofia Torreggiani¹, Lena Bichell¹, Gina Montealegre Sanchez⁵, Raphaela Goldbach-Mansky⁶ and Adriana de Jesus⁷, ¹Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Bethesda, MD, ²Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Clarksville, MD, ³Computational Systems Biology Section/NIAID/NIH, Bethesda, MD, ⁴NIH, Bethesda, ⁵NIAID/NIH, Rockville, MD, ⁶Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Potomac, MD, ⁷Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Silver Spring, MD
Background/Purpose: The disease progression of patients (pts.) with type-I interferon (IFN)-mediated diseases undergoing treatment with JAK1 and JAK2 inhibitors is monitored in part by measuring…
Abstract Number: 0172 • ACR Convergence 2020
Early Treatment and IL1RN Single Nucleotide Polymorphisms Affect Response to Anakinra in Systemic Juvenile Idiopathic Arthritis
Marianna Nicoletta Rossi¹, Manuela Pardeo², Denise Pires Marafon², Emanuela Sacco², Chiara Passarelli³, Claudia Bracaglia², Chiara Perrone³, Anna Tulone⁴, Giusi Prencipe⁵ and Fabrizio De Benedetti⁶, ¹Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Lazio, Italy, ²Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ³U.O.C. Laboratory of Medical Genetics, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ⁴Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ⁵Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, ⁶Division of Rheumatology, Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) represents 10-20% of all chronic arthritis during childhood. The interleukin 1 (IL-1) play a pivotal role in the pathogenesis…
Abstract Number: 0173 • ACR Convergence 2020
mTORC1 Signaling Promotes Monocytosis and Arthritis Development in IL-1 Receptor Antagonist-deficient Mice
Zhengping Huang¹, Ying Li², Alexandra Wactor³, Peter Nigrovic⁴ and Pui Lee⁵, ¹1.Guangdong Second Provincial General Hospital;2.Brigham and Women's Hospital;3.Harvard Medical School, BOSTON, MA, ²1.Brandeis University;2.Brigham and Women's Hospital, Waltham, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, Boston, ⁵1.Boston Children's Hospital;2.Brigham and Women's Hospital;3.Harvard Medical School, Newton, MA
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is potentially life-threatening disease characterized by prolonged fever, systemic inflammation and skin rash in addition to joint inflammation. Aberrant…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].